Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial

Trials. 2023 Jun 5;24(1):378. doi: 10.1186/s13063-023-07371-4.


Background: Cerebral amyloid angiopathy (CAA) is a disease caused by the accumulation of the amyloid-beta protein and is a major cause of intracerebral hemorrhage (ICH) and vascular dementia in the elderly. The presence of the amyloid-beta protein in the vessel wall may induce a chronic state of cerebral inflammation by activating astrocytes, microglia, and pro-inflammatory substances. Minocycline, an antibiotic of the tetracycline family, is known to modulate inflammation, gelatinase activity, and angiogenesis. These processes are suggested to be key mechanisms in CAA pathology. Our aim is to show the target engagement of minocycline and investigate in a double-blind placebo-controlled randomized clinical trial whether treatment with minocycline for 3 months can decrease markers of neuroinflammation and of the gelatinase pathway in cerebrospinal fluid (CSF) in CAA patients.

Methods: The BATMAN study population consists of 60 persons: 30 persons with hereditary Dutch type CAA (D-CAA) and 30 persons with sporadic CAA. They will be randomized for either placebo or minocycline (15 sporadic CAA/15 D-CAA minocycline, 15 sporadic CAA/15 D-CAA placebo). At t = 0 and t = 3 months, we will collect CSF and blood samples, perform a 7-T MRI, and collect demographic characteristics.

Discussion: The results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA. Therefore, our primary outcome measures are markers of neuroinflammation (IL-6, MCP-1, and IBA-1) and of the gelatinase pathway (MMP2/9 and VEGF) in CSF. Secondly, we will look at the progression of hemorrhagic markers on 7-T MRI before and after treatment and investigate serum biomarkers.

Trial registration: ClinicalTrials.gov NCT05680389. Registered on January 11, 2023.

Keywords: 7T MRI; Cerebral amyloid angiopathy; Cerebrospinal fluid; Dutch-type CAA; Minocycline; Randomized controlled trial.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Aged
  • Amyloid beta-Peptides
  • Anti-Bacterial Agents / pharmacology
  • Cerebral Amyloid Angiopathy* / complications
  • Cerebral Amyloid Angiopathy* / diagnostic imaging
  • Cerebral Amyloid Angiopathy* / drug therapy
  • Cerebral Amyloid Angiopathy, Familial* / complications
  • Cerebral Amyloid Angiopathy, Familial* / pathology
  • Cerebral Hemorrhage / etiology
  • Gelatinases
  • Humans
  • Inflammation
  • Minocycline
  • Neuroinflammatory Diseases
  • Randomized Controlled Trials as Topic


  • Amyloid beta-Peptides
  • Anti-Bacterial Agents
  • Gelatinases
  • Minocycline

Associated data

  • ClinicalTrials.gov/NCT05680389